Boundless Bio Inc (BOLD)

$1.16 -0.02 (-1.69%)
Market Cap 26.42M
Revenue (ttm) 0.00
Net Income (ttm) -65.36M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 122,300
Avg Vol 162,968
Day's Range N/A - N/A
Shares Out 22.39M
Stochastic %K 14%
Beta -0.90
Analysts Hold
Price Target $3.00

Company Profile

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. It also develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 dem...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 766 9912
Address:
10955 Alexandria Way, Suite 100, San Diego, United States
theyellowbear
theyellowbear Jan. 30 at 9:38 PM
$KOLD $BOLD new Fed chair nominee this morning who is not as dovish as expected, and the DXY was strongly rising. This is credited as one reason that Silver, Gold, risk assets sold off today. However, oil rose to highs, which is purportedly due to Iran risk also the BOIL started to risk later in the afternoon yesterday after falling on storage report (indicating storage is not an issue for price) but BOIL only rose in the last hours of the day in advance of the Iran situation this morning. So, I have to believe that after the Iran conflict is settled the March contract will return to $3.8
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 23 at 10:52 PM
$BOLD RSI: 55.88, MACD: 0.0145 Vol: 0.04, MA20: 1.24, MA50: 1.19 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
StockBraker
StockBraker Jan. 22 at 9:41 PM
$KOLD $BOLD Two big mistakes I see people making here. 1. These are leveraged ETFs which means they decay over time. If prices were to stay flat both of these would lose money over time. These are not designed to be buy and hold. 2. You need to be looking at NG futures and further out. If you were watching the Feb Henry Hub at all you would see this. Chart below is from 5am to just now. Explore on your own - https://www.cmegroup.com/markets/energy/natural-gas/natural-gas.quotes.html
1 · Reply
AlphaBull_10M
AlphaBull_10M Jan. 22 at 5:21 AM
$BOLD 3 days of sub freezing temps coming to Houston. Should be good for more rally until this passes. $UNG $NG_F $KOLD
2 · Reply
NYBomba
NYBomba Jan. 22 at 12:01 AM
$BOLD - 2026 is a big year for BOLD, let it ride…
0 · Reply
NYBomba
NYBomba Jan. 22 at 12:00 AM
$BOLD - • The most imminent data catalyst historically guided by the company was proof-of-concept data for BBI-355 in the second half of 2025. If that hasn’t been formally released yet, it’s the key near-term pipeline readout to watch. • BBI-940’s clinical data won’t be available until after the first-in-human trial begins and progresses, likely later in 2026. • Boundless’s press releases and SEC filings are the best source for exact dates once they announce topline results or trial summaries publicly.
0 · Reply
NYBomba
NYBomba Jan. 22 at 12:00 AM
$BOLD - Program Expected Milestone Timing (Company Guidance) BBI-355 (POTENTIATE) Initial clinical proof-of-concept data 2H 2025 (may be imminent/occurring) BBI-940 (KOMODO-1) Start of first-in-human trial 1H 2026 BBI-940 initial data Proof-of-concept clinical data (once trial proceeds) Likely later in 2026 or beyond
0 · Reply
NYBomba
NYBomba Jan. 21 at 11:59 PM
$BOLD - BBI-940 (KOMODO-1 first-in-human trial) • The FDA accepted the IND for BBI-940, a novel Kinesin oral degrader, enabling its first-in-human trial planned for the first half of 2026 (H1 2026).  • Because this trial hasn’t started yet, clinical data results won’t be available until after the trial progresses into dosing and follow-up, likely beyond mid-2026. Other Programs • Boundless previously deprioritized BBI-825 and some monotherapy arms, focusing resources on BBI-355 and BBI-940.  • There aren’t additional publicly scheduled data readouts beyond BBI-355 in H2 2025 / early 2026 and BBI-940 initiation in H1 2026 announced in press releases.
0 · Reply
JuggernautRaider
JuggernautRaider Jan. 21 at 8:30 PM
$BOLD you have to hold this for 2-3 years and hope BBI-940 shows incredible data while this company burns thru the rest of its cash. CCCC is a better oral degradation investment
1 · Reply
vu_jade
vu_jade Jan. 20 at 7:10 PM
$BOLD inch by inch
0 · Reply
Latest News on BOLD
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

Jan 20, 2026, 7:00 AM EST - 10 days ago

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 7:00 AM EST - 2 months ago

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 5, 2025, 7:00 AM EST - 3 months ago

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 4:05 PM EDT - 3 months ago

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 5, 2025, 7:00 AM EDT - 6 months ago

Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 4:58 PM EDT - 8 months ago

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Boundless Bio Announces Portfolio Prioritization and Runway Extension

May 23, 2025, 4:01 PM EDT - 9 months ago

Boundless Bio Announces Portfolio Prioritization and Runway Extension

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

May 9, 2025, 7:00 AM EDT - 9 months ago

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

Boundless Bio to Participate in the Needham Virtual Healthcare Conference

Apr 3, 2025, 7:00 AM EDT - 10 months ago

Boundless Bio to Participate in the Needham Virtual Healthcare Conference

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Mar 27, 2025, 7:00 AM EDT - 11 months ago

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Feb 26, 2025, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

Feb 3, 2025, 10:00 AM EST - 1 year ago

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

Boundless Bio Announces Pipeline and Leadership Updates

Dec 12, 2024, 4:01 PM EST - 1 year ago

Boundless Bio Announces Pipeline and Leadership Updates

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

Nov 25, 2024, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 7, 2024, 4:01 PM EST - 1 year ago

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

Nov 5, 2024, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

May 13, 2024, 7:00 AM EDT - 1 year ago

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

May 6, 2024, 8:00 AM EDT - 1 year ago

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

Mar 30, 2024, 1:00 AM EDT - 2 years ago

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

MMA MNDR NTCL NTHI ROTR UBXG WAY

Boundless Bio Announces Pricing of Initial Public Offering

Mar 27, 2024, 6:55 PM EDT - 2 years ago

Boundless Bio Announces Pricing of Initial Public Offering

U.S. IPO Weekly Recap: Tech IPOs Pop As End Of March Approaches

Mar 23, 2024, 12:20 AM EDT - 2 years ago

U.S. IPO Weekly Recap: Tech IPOs Pop As End Of March Approaches

ALAB AUNA INTJ MNDR RDDT

Boundless Bio Starts $100 Million U.S. IPO Plan

Mar 12, 2024, 4:16 PM EDT - 2 years ago

Boundless Bio Starts $100 Million U.S. IPO Plan

theyellowbear
theyellowbear Jan. 30 at 9:38 PM
$KOLD $BOLD new Fed chair nominee this morning who is not as dovish as expected, and the DXY was strongly rising. This is credited as one reason that Silver, Gold, risk assets sold off today. However, oil rose to highs, which is purportedly due to Iran risk also the BOIL started to risk later in the afternoon yesterday after falling on storage report (indicating storage is not an issue for price) but BOIL only rose in the last hours of the day in advance of the Iran situation this morning. So, I have to believe that after the Iran conflict is settled the March contract will return to $3.8
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 23 at 10:52 PM
$BOLD RSI: 55.88, MACD: 0.0145 Vol: 0.04, MA20: 1.24, MA50: 1.19 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
StockBraker
StockBraker Jan. 22 at 9:41 PM
$KOLD $BOLD Two big mistakes I see people making here. 1. These are leveraged ETFs which means they decay over time. If prices were to stay flat both of these would lose money over time. These are not designed to be buy and hold. 2. You need to be looking at NG futures and further out. If you were watching the Feb Henry Hub at all you would see this. Chart below is from 5am to just now. Explore on your own - https://www.cmegroup.com/markets/energy/natural-gas/natural-gas.quotes.html
1 · Reply
AlphaBull_10M
AlphaBull_10M Jan. 22 at 5:21 AM
$BOLD 3 days of sub freezing temps coming to Houston. Should be good for more rally until this passes. $UNG $NG_F $KOLD
2 · Reply
NYBomba
NYBomba Jan. 22 at 12:01 AM
$BOLD - 2026 is a big year for BOLD, let it ride…
0 · Reply
NYBomba
NYBomba Jan. 22 at 12:00 AM
$BOLD - • The most imminent data catalyst historically guided by the company was proof-of-concept data for BBI-355 in the second half of 2025. If that hasn’t been formally released yet, it’s the key near-term pipeline readout to watch. • BBI-940’s clinical data won’t be available until after the first-in-human trial begins and progresses, likely later in 2026. • Boundless’s press releases and SEC filings are the best source for exact dates once they announce topline results or trial summaries publicly.
0 · Reply
NYBomba
NYBomba Jan. 22 at 12:00 AM
$BOLD - Program Expected Milestone Timing (Company Guidance) BBI-355 (POTENTIATE) Initial clinical proof-of-concept data 2H 2025 (may be imminent/occurring) BBI-940 (KOMODO-1) Start of first-in-human trial 1H 2026 BBI-940 initial data Proof-of-concept clinical data (once trial proceeds) Likely later in 2026 or beyond
0 · Reply
NYBomba
NYBomba Jan. 21 at 11:59 PM
$BOLD - BBI-940 (KOMODO-1 first-in-human trial) • The FDA accepted the IND for BBI-940, a novel Kinesin oral degrader, enabling its first-in-human trial planned for the first half of 2026 (H1 2026).  • Because this trial hasn’t started yet, clinical data results won’t be available until after the trial progresses into dosing and follow-up, likely beyond mid-2026. Other Programs • Boundless previously deprioritized BBI-825 and some monotherapy arms, focusing resources on BBI-355 and BBI-940.  • There aren’t additional publicly scheduled data readouts beyond BBI-355 in H2 2025 / early 2026 and BBI-940 initiation in H1 2026 announced in press releases.
0 · Reply
JuggernautRaider
JuggernautRaider Jan. 21 at 8:30 PM
$BOLD you have to hold this for 2-3 years and hope BBI-940 shows incredible data while this company burns thru the rest of its cash. CCCC is a better oral degradation investment
1 · Reply
vu_jade
vu_jade Jan. 20 at 7:10 PM
$BOLD inch by inch
0 · Reply
SharkAttack1
SharkAttack1 Jan. 20 at 1:35 PM
$BOLD appreciating the management decision to terminate study early and focus on new IND to maximise cash. Also looks like 4 novel ecDNA targets identified too.
0 · Reply
slacktime
slacktime Jan. 20 at 12:18 PM
$BOLD BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026
0 · Reply
Dougie725
Dougie725 Jan. 20 at 12:11 PM
$BOLD why is this halted?
1 · Reply
AlphaBull_10M
AlphaBull_10M Jan. 19 at 5:05 AM
$NG_F NG future still holding 11% gain. I think it'll stay elevated long enough to let BOIL longs cash out. $BOLD $KOLD
0 · Reply
vu_jade
vu_jade Jan. 12 at 8:15 PM
$BOLD buy the dips Easy $5
0 · Reply
revuelto
revuelto Jan. 9 at 1:26 AM
$BOLD I like the clean balance sheet but no major catalysts…it’s likely to trade sideways for much of this year✌️
0 · Reply
NYBomba
NYBomba Jan. 9 at 1:21 AM
$BOLD - Golden Cross coming ...
1 · Reply
vu_jade
vu_jade Jan. 8 at 11:19 PM
$BOLD & the beautiful
0 · Reply
MKRReformed
MKRReformed Jan. 8 at 6:37 PM
$BOLD this has had very good inflow to outflow ratio the majority of the days since entry. One thing that I really like about it is the fact that vast majority of shares for holders are in the green, meaning if it runs there will be less bagholders selling as soon as they turn green and weighing it down more
0 · Reply
PurpleSquirrel2020
PurpleSquirrel2020 Jan. 8 at 3:45 PM
$BOLD so prime!
0 · Reply
vu_jade
vu_jade Jan. 8 at 12:22 PM
$BOLD could be getting started
1 · Reply
MKRReformed
MKRReformed Jan. 7 at 5:51 PM
$BOLD added bit few min ago
0 · Reply